Prompt empiric antibiotic therapy is of critical importance for patients with neutropenic fever. However, a major concern with important clinical consequences is the emergence of bacterial resistance to antibiotics. After using ceftazidime with a glycopeptide as initial empiric therapy for neutropenic fever, we were confronted with a 75% reduced susceptibility rate to ceftazidime of inducible Enterobacteriaceae collected in 1994. The initial empiric therapy was therefore replaced in May 1995 by a combination of cefepime with amikacin, with addition of a glycopeptide after 48 h if necessary. After this change, we observed a significant decrease in reduced susceptibility of inducible Enterobacteriaceae, not only to ceftazidime, but also to amikacin, cotrimoxazole and ciprofloxacin. There was also a decrease in reduced susceptibility of non-inducible Enterobacteriaceae, such as Klebsiella spp, to ceftazidime. The reduction of resistance may be related at least in part to the combined use of cefepime together with an aminoglycoside. This study shows that it is possible to reverse bacterial resistance by modifying the antibiotic regimen used.
Introduction
Despite significant improvements in supportive care, infection remains an important cause of morbidity and mortality for patients with hematological malignancies undergoing intensive chemotherapy and/or hematopoietic stem cell transplantation. Therefore, rapid initiation of empiric antimicrobial therapy at the onset of neutropenic fever is mandatory. 1 Gram-negative bacteremia is an important cause of death in febrile neutropenic cancer patients, accounting for around 30% of deaths by infection in some series. 1 Among these Gram-negative bacteria, organisms capable of producing group I ␤-lactamases have emerged in recent years as a major cause of nosocomial infections. These bacteria can produce a cephalosporinase that is able to inactivate most of the cephalosporins. 2, 3 The majority of these bacteria are inducible Enterobacteriaceae (Enterobacter spp, Serratia spp, Citrobacter spp, Morganella morganii, Providencia spp, Proteus vulgaris, Pantoea agglomerans). The relationship between the emergence of resistance of group I ␤-lactamase-producing organisms and the prior use of extended-spectrum cephalosporins is now clearly proven. 2 Another risk factor of developing resistance to extended-spectrum cephalosporins is the amount of previously used antibiotics. 2 The clinical consequence is that development of resistance may become particularly devastating in neutropenic patients. Chow et al 4 1991 that isolation of multiresistant Enterobacter sp in the initial blood culture was associated with a higher mortality rate than isolation of a more sensitive Enterobacter sp. King et al 5 was able to demonstrate that after the decision to use amikacin as the sole formulary aminoglycoside (because of a high reduced susceptibility rate to gentamicin and tobramycin), the incidence of bacteremia-associated death decreased significantly. In 1997, the Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America Joint Committee also stated that antimicrobial resistance results in increased mortality. 6 After long-term use of ceftazidime, a third generation cephalosporin used at the Division of Hematology since February 1991, we observed a reduced susceptibility of inducible Enterobacteriaceae to ceftazidime in 75% of the isolates collected in 1994. The aim of our study was to decrease this reduced susceptibility by changing the antibiotic policy for treatment of neutropenic fever from an initial empiric therapy of ceftazidime and a glycopeptide (vancomycin or teicoplanin), to an empiric combination therapy of cefepime and amikacin, followed by addition of a glycopeptide after 48 h if necessary. Cefepime, a 'fourth generation' cephalosporin with a spectrum covering Gram-negative and part of Gram-positive bacteria, 7 had never been used before in our hospital. The oral prophylactic regimen remained unchanged.
Materials and methods
Patients with febrile neutropenia at the Division of Hematology were treated with ceftazidime (2 g three times a day i.v.) plus vancomycin (1 g twice a day i.v.) or (less frequently) teicoplanin (1200 mg/day i.v., followed by 800 mg/day i.v.) until the end of April 1995. From May 1995 until December 1997, we decided to change this antibiotic regimen to cefepime (2 g three times a day i.v.) and amikacin (15 mg/kg/day i.v.). Vancomycin or teicoplanin, were added after 48 h based on clinical (eg persistent fever) or microbiologic results. If fever still persisted for at least an additional 48 h, ceftazidime or cefepime were replaced by imipenem-cilastatine or meropenem (1 g three times a day i.v.). Amphotericin B (50 mg/day i.v.) was added in case of persistent fever. Neutropenic fever was defined as neutropenia with Ͻ1000 peripheral blood neutrophils/mm 3 and fever as a temperature of у38.5°C once or 38.0°C twice within 4 h. The oral antibiotic prophylaxis policy remained unchanged: fluoroquinolones (ciprofloxacin, ofloxacin) or trimethoprim/ sulfamethoxazole (the latter for bone marrow transplantation patients). Oral antibiotic prophylaxis was discontinued after initiation of empiric antibiotic regimen.
'Inventory' cultures were taken once a week from all neutropenic patients (with or without fever), and twice a week Table 1 Evolution in antibiotic use (in units of defined daily doses (DDD): estimation of the total amount of the drug an adult will receive during 1 day of therapy)
Antibiotic
January-June July-December January-June July-December January-June The quantity corresponding to 1 unit of DDD is indicated between parentheses for each antibiotic.
from transplantation patients. They consisted of nine skin swabs (nose, throat, ears, axilla, groin, perianal region, vagina or preputium), a urine culture and a stool culture. In case of neutropenic fever, hemocultures, urine cultures and throat swabs were taken. Suspected foci of infection were also cultured. Clinical isolates obtained in 1994, 1995, 1996 and 1997, respectively, were: 376 (from 127 patients), 363 (from 125 patients), 359 (from 139 patients) and 438 (from 150 patients).
All bacterial isolates were identified with an in-house method and tested for their antibiotic susceptibility using Kirby-Bauer disk diffusion according to the standards of the National Committee for Clinical Laboratory standards (NCCLS). 8, 9 Breakpoints were based on the NCCLS guidelines. 9 The reduced susceptibility rates were statistically compared between 1994 and 1997 using the 2 test.
Results
The changes in antibiotic use during the study period are displayed in Table 1 . A significant reduction and increase of the use of ceftazidime and cefepime, respectively, is noted. The use of amikacin also increased, while that of the glycopeptides, vancomycin and teicoplanin, remained stable. When considering the patterns of reduced susceptibility covering the period between 1994 and 1997, we noted a strong decrease in reduced susceptibility of the inducible Enterobacteriaceae to ceftazidime, ceftriaxone, amikacin, cotrimoxazole and ciprofloxacin (Table 2) .
Different inducible Enterobacteriaceae species were represented during the years, suggesting that there was no spread of one bacterial clone of inducible Enterobacteriaceae (Table 3) . We also examined reduced susceptibility rates of noninducible Enterobacteriaceae that can be subdivided into two groups: E. coli (Table 4 ) and the other non-inducible Enterobacteriaceae. The other non-inducible Enterobacteriaceae showed a decreased reduced susceptibility rate to ceftazidime (Table 5 ). In the latter category, Klebsiella spp also showed a strong decrease in reduced susceptibility to ceftazidime. Finally, there was no reduced susceptibility of Pseudomonas aeruginosa to ceftazidime.
Discussion
Ceftazidime and glycopeptides were extensively used on the hematology ward as initial empiric treatment for neutropenic fever. In April 1995, we observed a reduced susceptibility of inducible Enterobacteriaceae to ceftazidime in 75% of the isolates collected in 1994. Therefore, a change in our antibiotic policy was mandatory. Thus, in May 1995 we changed the initial empiric antibiotic policy for neutropenic fever by introducing the combination of cefepime and amikacin, with addition of a glycopeptide after 48 h, if necessary. Oral prophylactic therapy remained unchanged.
A prospective study showed that emergence of reduced susceptibility of Enterobacter isolates occurred more often to third generation cephalosporins (19%) than to aminoglycosides (1%) or to other beta-lactams (0%). 4 Jacobson et al 2 also proved that prior exposure to ceftizoxime, cefotaxime and ceftazidime was associated with the isolation of organisms resistant to extended-spectrum cephalosporins. As little as 1 day of therapy with ceftazidime puts patients at risk of having an isolate resistant to extended-spectrum cephalosporins. Increasing ceftazidime reduced susceptibility among Enterobacter spp, Klebsiella pneumoniae and P. aeruginosa in the USA and Europe has been documented. 10 Ballow and Schentag 11 reported in 1992 a decline in E. cloacae susceptibility to ceftazidime during an increased use of ceftazidime and aminoglycosides as empiric therapy for nosocomial infections. After restricted use of ceftazidime during a 10-month period, the susceptibility of E. cloacae to ceftazidime was restored (from 54% to 75%).
In our study, after an 8-month period, the reduced susceptibility patterns clearly improved for inducible Enterobacteriaceae. Ceftazidime, amikacin, ceftriaxone, cotrimoxazole and ciprofloxacin reduced susceptibility rates decreased significantly (Table 2 ). In 1996 and 1997, when the new combination therapy was continued, the reduced susceptibility rates remained stable or decreased further. Antibiotic resistance of the other non-inducible Enterobacteriaceae also decreased, especially ceftazidime for Klebsiella. Although the oral prophylactic therapy remained unchanged, reduced susceptibility of inducible Enterobacteriaceae to ciprofloxacin and cotrimoxazole also decreased. The reason for this is unclear. This phenomenon can be explained in several ways. First, cefepime is a new extended-spectrum cephalosporin which has activity against aerobic Gram-negative and Gram-positive bacteria. It is resistant to degradation by several plasmid and chromosomally mediated beta-lactamases. Cefepime shows low affinity and no inducing capacity for these beta-lactamases. Cefepime is, in vitro, active against ceftazidime-resistant Enterobacteriaceae. 12 Second, combination therapy with amikacin could act synergistically against Gram-negative bacteria. That the combination of amikacin and cefepime at least partly played a role in reducing the reduced susceptibility rate of inducible Enterobacteriaceae, can be deduced from the observation that the amikacin reduced susceptibility rate also dropped, as compared to a period where this antibiotic was not routinely used as a first-line medication for neutropenic fever. In conclusion, this study demonstrates that it was possible to reverse the trend of antibiotic resistance of inducible and non-inducible Enterobacteriaceae by introducing a combination therapy, including cefepime and amikacin.
